The invention provides methods for analyzing cardiovascular disease risk. Methods of the invention provide a probability of an individual developing cardiovascular disease based on parameters including blood levels of sdLDL-C, ApoA-I in α-1 HDL, and Lp(a) along with information about the patient's age and history of blood pressure treatment, smoking, and diabetes. Methods of the invention do not rely on standard risk factor measurements, such as CRP, total cholesterol, body mass index, weight, triglycerides, and the like.

Methods, software, systems, and apparatuses that can identify bivalent reaction mechanisms using surface plasmon resonance (SPR) are provided. Methods, software, systems, and apparatuses that can identify SPR sensorgrams that fit a bivalent analyte model are also provided. A method can include recording multiple SPR sensorgrams with an analyte at different concentrations, fitting each sensorgram with a single exponential function with exponents, determining the exponents for each sensorgram and R.sup.2 values for each sensorgram, and plotting R.sup.2 versus analyte concentration and determining if an optimal concentration exists.

A computer-implemented method for determining minor variants. The method includes receiving electropherogram sequence data from a test sample, identifying any non-primary peaks in the electropherogram, and characterizing identified non-primary peaks using at least one signal feature. The method may further include analyzing the at least one signal feature across identified non-primary peaks to identify variant candidates, evaluating at least one peak characteristic of each of the identified variant candidates, and classifying variant candidates as bona fide variants based on the evaluation of peak characteristics.

The present invention relates to a disease-specific metabolite profile, and particularly to a biomarker composition obtained by screening from urine-specific metabolite profiles of coronary heart disease subjects. The present invention also relates to a use of the biomarker compositions in risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease, and to a method for risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease. The biomarker composition as provided by the present invention can be used for early diagnosis of coronary heart disease and has high sensitivity, good specificity and good application prospects.

Methods and systems for detecting abnormal karyotypes are disclosed. An example method can comprise determining read coverage data, allele balance distributions of heterozygous SNPs, and chromosomal segments where heterozygosity is not observed. The methods and systems can then determine one or more metrics which can be indicative of abnormal karyotype(s).

In accordance with certain exemplary embodiments of the present disclosure, exemplary visualization system, method, procedure and computer-accessible medium can be provided, which individually and/or collectively can be called, e.g., ImmunoRuler (IR). Certain exemplary embodiments of the exemplary IR in accordance with the present disclosure can be used for, e.g., comparing two groups of objects with specific and distinguished properties, such as a group of case subjects with a particular disease and a group of control subjects without that particular disease, and/or a group of subjects with a particular disease who are given a treatment and a group of subjects with the same disease but under another treatment or no treatment at all.

The present disclosure describes systems and methods for determining and flagging sequences that deviate from one or more reference sequences. Phylogenetic methods are used for determining the evolutionary history and evolutionary distances of sample isolates. The evolutionary distances of sample isolates may be compared to each other and/or reference isolates. Based on a comparison of the evolutionary distances, a determination of deviance is made for a sample sequence. The sample sequence is flagged for further analysis to determine the cause of deviation.

Systems, methods and computer-readable media are provided for determining the amount of sequencing required to achieve a target sequencing quality of a genetic sample to be sequenced. The method comprises receiving a genetic sample and sequencing a portion of the genetic sample. A sequencing quality metric belonging to a category of sequencing quality metrics is generated from the sequencing. The amount of sequencing of the genetic sample required to achieve the target sequencing quality is determined by inputting the sequencing quality metric into a trained model. A system is also disclosed for genetic sequencing. Corresponding methods and computer-readable media are also provided.

Embodiments of a method and system for characterizing a skin-related condition in relation to a user can include one or more of: a handling network operable to collect containers comprising material from a set of users, the handling network comprising a sequencing system operable to determine microorganism sequences from sequencing the material; a microbiome characterization system operable to: determine at least one of microbiome composition data and microbiome functional diversity data based on the microorganism sequences, collect supplementary data associated with the skin-related condition for the set of users, and transform the supplementary data and the at least one of the microbiome composition data and the microbiome functional diversity data into a characterization model; and a therapy system operable to promote a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.

The present invention relates to the field of diagnostic methods. Specifically, the present invention relates to a method for assessing a quality of a biological sample comprising the steps of: (a) providing a table comprising a number of entries, wherein each entry comprises a compound, at least one parameter, and a scoring factor, wherein, in case the compound is a natural compound it refers to an analyte, or in case the compound is an artificial compound it refers to a ratio of two analytes, wherein the at least one parameter is related to the compound, wherein the parameter related to the analyte is derived from at least one recorded value for the analyte while the parameter related to the ratio of the two analytes is derived from a ratio of at least one recorded value of the two analytes, and wherein the scoring factor is related to the compound; (b) determining for each of the compounds in the table a compound quality score, wherein the compound quality score is determined by taking a multiple value of the scoring factor related to the compound, wherein, depending on the actual value of the at least one parameter related to the compound, the multiple value is selected, wherein the multiple value comprises an integral number or a decimal number by which the scoring factor related to the compound is multiplied; (c) deriving at least one sample quality score by summing up the compound quality scores for the compounds in the table as determined in step (b); and (d) comparing the at least one sample quality score as derived in step (c) with at least one reference quality score, by which comparison the quality of the sample is assessed. The invention further relates to tools for performing the mentioned method, such as a device and a kit, as well as a use of components or a detection agent therefore for assessing the quality of a biological sample. The invention particularly provides for, preferably automatically, identifying a correct sample type and, concurrently, assessing the sample quality, in particular, with respect to its preanalytical phase.